Mylod-At

# Mylod-at ## Overview - **Classification**: Selective Serotonin Reuptake Inhibitor (SSRI) - **Mechanism**: Potent and selective inhibitor of serotonin reuptake in the CNS, leading to increased serotonin activity. ## Primary Indications 1. **Major Depressive Disorder (MDD)** - Treatment of depressive episodes 2. **Generalized Anxiety Disorder (GAD)** - Management of anxiety symptoms 3. **Panic Disorder (PD)** - Prevention of panic attacks ## Adult Dosing ### Standard Dosing **Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD)** - **Dose**: **10 mg** - **Frequency**: Once daily - **Route**: Oral - **Duration**: Long-term, as determined by clinical response **Panic Disorder (PD)** - **Dose**: Initiate with **5 mg** - **Frequency**: Once daily for one week, then increase to **10 mg** once daily - **Route**: Oral - **Duration**: Long-term, as determined by clinical response ### Dose Adjustments - **Renal Impairment**: No dose adjustment needed for mild to moderate impairment. Use caution in severe impairment (CrCl < 30 mL/min). - **Hepatic Impairment**: Initiate with **5 mg** once daily. Max dose **10 mg** daily. - **Elderly Patients**: Initiate with **5 mg** once daily. Max dose **10 mg** daily. ## Pediatric Dosing ### Neonates (0-28 days) - Use generally not recommended due to lack of safety and efficacy data. - Risk of persistent pulmonary hypertension of the newborn (PPHN) if exposed late in pregnancy. - **Special Notes**: Consider risks vs. benefits carefully if maternal use continues. ### Infants (1-12 months) - Not approved for use in this age group. ### Children (1-12 years) - Not approved for use in this age group. ### Adolescents (13-18 years) - **Major Depressive Disorder**: Initiate with **10 mg** once daily. May increase to **20 mg** daily after at least 3 weeks. - **Maximum**: **20 mg** once daily. - **Special Notes**: Monitor closely for suicidality, especially at treatment initiation or dose changes. ## Safety Information ### Contraindications - **Absolute**: Concomitant use with MAOIs (risk of serotonin syndrome). - **Absolute**: Known hypersensitivity to Mylod-at or any excipients. - **Absolute**: Concomitant use with pimozide. - **Relative**: Uncontrolled narrow-angle glaucoma. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, insomnia, ejaculation disorder, diarrhea. - **Common (1-10%)**: Dry mouth, somnolence, sweating, fatigue, dizziness, anorexia, tremor. - **Serious but Rare**: Serotonin syndrome, suicidal ideation, prolonged QT interval, seizures. ### Key Drug Interactions - **MAOIs**: Increased risk of serotonin syndrome; separate by at least 14 days. - **QT-prolonging drugs**: Increased risk of ventricular arrhythmias; avoid co-administration if possible. - **NSAIDs/Anticoagulants**: Increased risk of bleeding due to platelet aggregation inhibition. - **Triptans**: Increased risk of serotonin syndrome. ## Monitoring & Follow-up - **Before Treatment**: Baseline ECG (if cardiac risk factors present), psychiatric evaluation. - **During Treatment**: Monitor for symptom improvement, adverse effects. - **During Treatment**: Monitor for suicidality, especially in young adults and children (frequent during first few weeks). - **During Treatment**: Electrolytes (if at risk for QT prolongation). - **Clinical Signs**: Changes in mood, agitation, confusion, tremor (serotonin syndrome). ## Clinical Pearls - 💡 **Tip 1**: Administer in the morning or evening without regard to food. Evening dosing may help with insomnia. - 💡 **Tip 2**: Full therapeutic effect may take 2-4 weeks; counsel patients on this delay. - 💡 **Tip 3**: Do not abruptly discontinue; taper dose gradually to avoid withdrawal symptoms. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.